Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    The Case of the Cord Blood Match
    Clinical practice
    The Case of the Cord Blood Match
    March 26, 2021
    Empower Recent Graduate Nurses to Be Patient Advocates
    Nurse empowerment
    Empower Recent Graduate Nurses to Be Patient Advocates
    March 19, 2021
    Shared Governance Committees Empower Nurses to Use Their Voice
    Nurse empowerment
    Shared Governance Committees Empower Nurses to Use Their Voice
    March 12, 2021
    Nursing Students Connect Beyond the Classroom With ONS Resources
    Nursing education
    Nursing Students Connect Beyond the Classroom With ONS Resources
    March 05, 2021
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    COVID-19
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    February 19, 2021
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • News & Views

    Clinical practice

    Oral Adherence With Nerlynx® (Neratinib) Tablets: Conversation With an Expert, Part 1
    Oral adherence

    Oral Adherence With Nerlynx® (Neratinib) Tablets: Conversation With an Expert, Part 1

    This is the third in a series detailing some of the general factors to consider around patient adherence to oral medications, and ways to support patients receiving neratinib.

    October 26, 2018
    Oral Adherence With Nerlynx® (Neratinib) Tablets: Patient Case
    Oral adherence

    Oral Adherence With Nerlynx® (Neratinib) Tablets: Patient Case

    AS is a 58-year-old woman who was diagnosed at age 55 with a right infiltrating ductal carcinoma of the breast, identified as grade III, ER and PR positive, and HER2 positive. She had bilateral mastectomy, and tumor size was noted to be 2.8 cm. She had a positive sentinel lymph node. She was staged at IIB (pT2, pN1, M0). Her left breast was noted to have usual ductal epithelial hyperplasia and a 1.2 cm fibroadenoma. AS’s genetic testing revealed a BRCA1 mutation (BRCA1 c.3748G>T [p.Glu1250*]), which may confer an increased risk for breast cancer in the range of 46%–87%, and 39%–63% risk for ovarian cancer by age 70. As her patient history shows, she has some risk factors for nonadherence, including no support at home and some financial issues. Throughout her care, the team worked to communicate and prepare AS to help ensure adherence as much as possible.

    October 26, 2018
    Oral Adherence With Nerlynx® (Neratinib) Tablets: Introduction
    Oral adherence

    Oral Adherence With Nerlynx® (Neratinib) Tablets: Introduction

    The cancer treatment landscape has shifted with the emergence of new, targeted therapies. Development and use of oral oncolytics, targeted cancer therapies that can be taken by patients orally in their own homes, has increased in recent years. This increase is due in part to research in extra- and intracellular signaling pathways. By interfering with or blocking these signals, targeted drugs have become standard agents in cancer therapy. Oral oncolytics currently account for about 25% of the oncology pipeline of drugs in clinical development, and experts project that oral oncoloytic use will continue to rise.

    October 26, 2018
    Institution Meets Magnet Designation by Incorporating ONS Standards in Care Delivery
    Oncology nurse influence

    Institution Meets Magnet Designation by Incorporating ONS Standards in Care Delivery

    To meet or maintain Magnet designation, the American Nurses Credentialing Center (ANCC) Magnet Recognition Program expects organizations to incorporate specialty standards and guidelines into the care delivery system. 

    October 19, 2018
    Neuroendocrine Prostate Cancer Subtype Is Aggressive and More Common Than Expected
    Research

    Neuroendocrine Prostate Cancer Subtype Is Aggressive and More Common Than Expected

    Nearly 20% of men with metastatic, castration-resistant prostate cancer had tumors that developed into the treatment-emergent small-cell neuroendocrine (t-SCNC) subtype, which is associated with shorter survival than other subtypes, according to findings from a study published in the Journal of Clinical Oncology.

    October 17, 2018
    FDA Approves Talazoparib for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Talazoparib for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer

    On October 16, 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib, a poly (ADP-ribose) polymerase inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2‑negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.

    October 16, 2018
    Priming Lines With Drug May Reduce Hypersensitivity Reactions From Rituximab
    Clinical practice

    Priming Lines With Drug May Reduce Hypersensitivity Reactions From Rituximab

    Monoclonal antibody cancer treatments such as rituximab have a high risk for hypersensitivity reactions from cytokine release syndrome. The symptoms, which can range from mild to life threatening, result from tumor antigen-expressing cells releasing cytokines (e.g., tumor necrosis factor, interleukin, interferon) into the blood as they are destroyed. Symptoms include fever, chills, rigors, rash, headache, hypotension, shortness of breath, bronchospasm, nausea, vomiting, and abdominal pain.

    October 09, 2018
    Which Gene is Associated With Cowden Syndrome (Multiple Hamartoma Syndrome)?
    Genetics & genomics

    Which Gene Is Associated With Cowden Syndrome (Multiple Hamartoma Syndrome)?

    Which Gene is Associated With Cowden Syndrome (Multiple Hamartoma Syndrome)?

    A. APC 

    B. VHL 

    C. TP53 

    D. PTEN

    October 05, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Cemiplimab-RWLC for Metastatic or Locally Advanced CSCC

    On September 28, 2018, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

    October 02, 2018
    FDA Approves Duvelisib for Adult Patients With Relapsed or Refractory CLL or SLL
    U.S. Food and Drug Administration (FDA)

    FDA Approves Duvelisib for Adult Patients With Relapsed or Refractory CLL or SLL

    On September 24, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to duvelisib for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.

    September 25, 2018
    Which Nonpharmacologic Intervention Is Recommended for Cancer-Related Fatigue?
    Clinical practice

    Which Nonpharmacologic Intervention Is Recommended for Cancer-Related Fatigue?

    Which of the following nonpharmacologic interventions is currently recommended for practice for cancer-related fatigue?

    A. Acupressure

    B. Meditation

    C. Exercise

    D. Tai Chi

    September 21, 2018
    How Advanced Practice Nurses Can Recognize It; Report It in an Era of Fast-Track Drug Approvals
    Advanced practice nursing (APN)

    How Advanced Practice Nurses Can Recognize It; Report It in an Era of Fast-Track Drug Approvals

    It takes an average of 12 years to move a drug from a new application to approval for a specific indication. Twelve years of clinical trials, documentation of several endpoints, and data surrounding incidence of observed adverse events and expected severity. Twelve years until a broader subset of patients can access the drug. 

    September 20, 2018
    The Case of the CAR T-Cell Toxicity Test
    Clinical practice

    The Case of the CAR T-Cell Toxicity Test

    Wilson was diagnosed with B-cell lymphoma three days after his 63rd birthday. He underwent chimeric antigen receptor (CAR) T-cell therapy after his disease failed to respond to two lines of systemic chemotherapy.

    September 18, 2018
    First-Line Osimertinib for Metastatic Non-Small Cell Lung Cancer
    Treatments

    First-Line Osimertinib for Metastatic Non-Small Cell Lung Cancer

    Lung cancer is the second most common cancer in both men and women (after skin cancer) and is the leading cause of cancer death among both men and women. Histology has become an important determinant in choosing therapy for various types of cancer, including non-small cell lung cancer (NSCLC). Currently, biomarker testing is the standard of care in lung cancer; with biomarker testing, patients likely to respond to targeted therapy can be identified. As the number of targeted agents continues to increase, so does the demand for continued biomarker testing and adequate tumor tissue samples.

    September 14, 2018
    Global Cancer Burden Rises to 18.1 Million New Cases and 9.6 Million Deaths in 2018
    Research

    Global Cancer Burden Rises to 18.1 Million New Cases and 9.6 Million Deaths in 2018

    As global populations grow, so does the cancer burden, a new study from the World Health Organization’s International Agency for Research on Cancer (IARC) reported. The results of the latest analysis of the incidence and mortality of 36 types of cancer in 185 countries were published in CA: A Cancer Journal for Clinicians in September 2018.

    September 13, 2018
    FDA Approves Moxetumomab Pasudotox-tdfk for Hairy Cell Leukemia
    U.S. Food and Drug Administration (FDA)

    FDA Approves Moxetumomab Pasudotox-tdfk for Hairy Cell Leukemia

    On September 13, 2018, the U.S. Food and Drug Administration (FDA) approved moxetumomab pasudotox-tdfk (Lumoxit), a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

    September 13, 2018
    Evidence Is Building for Acupuncture as an Opioid Alternative for Cancer Pain
    Complementary therapy

    Evidence Is Building for Acupuncture as an Opioid Alternative for Cancer Pain

    Pain is the most common and debilitating side effect that patients with cancer experience. Contributing factors include the disease itself via tumor invasion on surrounding tissue and bone; nerve compression; treatments including chemotherapy, radiotherapy and surgery, especially chemo-induced peripheral neuropathy (CIPN), which can be disabling; and aromatase inhibitors that can cause persistent diffuse joint pain. In addition, pain that “breaks through” continuous pain medicine can be difficult to predict and control.

    September 12, 2018
    How Inhaled Cannabis May Contribute to Pulmonary Toxicity in Patients With Cancer
    Clinical practice

    How Inhaled Cannabis May Contribute to Pulmonary Toxicity in Patients With Cancer

    As medical use of cannabis is increasingly legalized across the United States, oncology nurses need to become more familiar with the implications of patients using it for cancer symptom management. According to Merkle and Tavernier in their article in the August 2018 issue of the Clinical Journal of Oncology Nursing, little research has been conducted in medical cannabis use and the efficacy and toxicity of cancer treatment. Their article reviewed current literature to better understand the effects that cannabis may have on the lungs in patients with cancer.  

    September 11, 2018
    What Does the “E” Mean in the National Cancer Institute’s “ABCDE” Tool for Recognizing Melanoma?
    Melanoma

    What Does the “E” Mean in the National Cancer Institute’s “ABCDE” Tool for Recognizing Melanoma?

    What does the “E” mean in the National Cancer Institute’s “ABCDE” tool for recognizing melanoma?

    A. Extension

    B. Evolution

    C. Equal

    D. Expand

    August 31, 2018
    FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma

    On August 16, 2018, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules for first-line treatment of patients with unresectable hepatocellular carcinoma.

    August 16, 2018
    An Oncology Nurse’s Guide to Targeted Therapy
    Targeted therapy

    An Oncology Nurse’s Guide to Targeted Therapy

    Whereas chemotherapy induces apoptosis by interfering with cell division of both cancerous and healthy cells, targeted therapy exploits targets, proteins, enzymes, or genes specific to malignant cells through a variety of mechanisms of action, which helps prevent drug resistance. The agents work by either inhibiting angiogenesis, blocking chemical signals that tell cells to divide or carry out normal function, or delivering toxic substances to a cell. 

    August 14, 2018
    Which of the Following Isn’t a Breast Cancer Surveillance Recommendation?
    Clinical practice

    Which of the Following Isn’t a Breast Cancer Surveillance Recommendation?

    Mrs. Johnson has just been told she's in remission from breast cancer. Which of the following isn't a surveillance recommendation?

    A. Routine mammography screening every 12 months for locally recurrent tumors or new primary cancers  

    B. Screening for cervical and colorectal cancer every six months for two years 

    C. Gynecologic evaluation every 12 months for women on tamoxifen therapy who have an intact uterus 

    D. Detailed history and physical examination every three to six months for three years  

    August 09, 2018
    TNM Gets an Upgrade in Eighth Edition Staging Guidelines
    Clinical practice guidelines

    TNM Gets an Upgrade in Eighth Edition Staging Guidelines

    Nearly a century ago, cancer staging was a simple categorization of disease as either local, regional, or distant. Then in the 1940s, a French surgeon developed the concept for a staging system that uses the size of the primary tumor (T), its lymphatic involvement (N), and the presence of metastases (M) to stage a patient’s cancer based on the anatomic extent of the disease at the time of diagnosis.

    August 09, 2018
    FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sézary Syndrome
    U.S. Food and Drug Administration (FDA)

    FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sézary Syndrome

    On August 8, 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab-kpkc (Poteligeo) for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.

    August 08, 2018
    Annual Cancer Report Shows New Trends in Prostate Cancer
    Prostate cancer

    Annual Cancer Report Shows New Trends in Prostate Cancer

    After years of decline, the death rate trend for prostate cancer has stabilized from 2013–2015, according to the National Cancer Institute’s (NCI’s) 2018 Annual Report to the Nation on the Status of Cancer.

    August 01, 2018
    drug spill safe handling
    Safe handling

    Which of the Following Drug Spills Doesn’t Require a Full-Facepiece, Chemical Cartridge-Type Respirator or PAPR?

    Which of the following drug spills doesn’t require a full-facepiece, chemical cartridge-type respirator or PAPR during clean up?

    A. 5-Fluorouracil 

    B. Cyclophosphamide 

    C. Adriamycin  

    D. Nitrogen mustard 

    July 26, 2018
    The Oncology Nurse Experience in Managing Adverse Events in Patients Receiving Ibrutinib
    Adverse events

    The Oncology Nurse Experience in Managing Adverse Events in Patients Receiving Ibrutinib

    Ibrutinib is a first-in-class Bruton’s tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The drug’s approval was based on results from the multicenter, open-label, phase III RESONATE trial.

    July 25, 2018
    FDA Approves Ivosidenib for Relapsed or Refractory AML
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ivosidenib for Relapsed or Refractory AML

    On July 20, 2018, the U.S. Food and Drug Administration (FDA) approved ivosidenib for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.

    July 20, 2018
    What Happens if Patients With Cancer Have Bedbugs?
    Safety

    What Happens if Patients With Cancer Have Bedbugs?

    Lurking in the dark corners of bedrooms across the country, unseen figures wait to feast of the blood of humans and animals alike. When the lights go dark, they come out for dinner. No, they’re not vampires or mystical beasts—they’re bedbugs. These parasitic insects feed exclusively on the blood of humans and animals and are a prevalent parasite in the United States. 

    July 19, 2018
    FDA Expands Ribociclib Indication in HR-Positive, HER2-Negative Advanced, Metastatic Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Expands Ribociclib Indication in HR-Positive, HER2-Negative Advanced, Metastatic Breast Cancer

    On July 18, 2018, the U.S. Food and Drug Administration (FDA) expanded the indication for ribociclib (Kisqali) in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.

    July 18, 2018
    FDA Approves Enzalutamide for Castration-Resistant Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Enzalutamide for Castration-Resistant Prostate Cancer

    On July 13, 2018, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi), for patients with castration-resistant prostate cancer.

    July 17, 2018
    The Case of the Coercive Consent
    Clinical practice

    The Case of the Coercive Consent

    Betty, age 70, was diagnosed with metastatic colon cancer and started treatment with FOLFOX. Her medical oncologist changed the treatment to capcitabine after Betty developed grade 3 peripheral neuropathy. Because of disease progression, bevacizumab was added to her treatment plan. She lives with her daughter, is insured by Medicare, and receives $800 per month from Social Security.

    July 17, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Ipilimumab for Certain Metastatic Colorectal Cancers

    On July 10, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to ipilimumab for use in combination with nivolumab for the treatment of patients 12 years of age and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

    July 12, 2018
    ONS Congress

    APNs Give Practical Advice for Establishing Clinics and Implementing Programs

    Advanced practice nurses (APNs) are creating new and innovative programs that educate patients and help them live better, healthier lives. Lorraine Drapek, DNP, FNP-BC, AOCNP®, Geline Joy Tamayo, MSN, RN, ACNS-BC, OCN®, TTS, Suzanne McGettigan, MSN, CRNP, AOCN®, ANP-BC, and Edward Bentlyewski, MSN, APN, NP-C, AOCNP®, discussed their experiences with APN-run clinics and program implementation during a session at the 43rd Annual Congress in Washington, DC.

    July 12, 2018
    What to Do When Your Patients Talk About Medical Aid in Dying
    End of life (EOL)

    What to Do When Your Patients Talk About Medical Aid in Dying

    Despite groundbreaking treatments, novel medications, fast-tracked drug approvals, and cutting-edge science, a terminal diagnosis is still a reality for many patients with cancer. Having end-of-life discussions with patients and their family members is a difficult part of oncology nursing, but it’s necessary to provide the highest quality of care and education possible. With more news reports emerging about states introducing—and passing—medical aid in dying legislation, oncology nurses will face questions about the process from patients and caregivers.

    July 02, 2018
    Latest FDA Cancer Treatment Approvals Trend Toward New Indications
    U.S. Food and Drug Administration (FDA)

    Latest FDA Cancer Treatment Approvals Trend Toward New Indications

    What is unique about the most recent U.S. Food and Drug Administration (FDA) approvals in the oncology/hematology area is that almost all are for new indications of existing agents as opposed to new agents. This is not surprising because many of the agents target specific bioassays or tumor markers instead of a specific disease site. Oncology nurses need to be aware of the changes because treatments that they have become accustomed to giving for one indication may soon be given for others as well.

    June 28, 2018
    How One Institution Used Evidence-Based Practice to Reduce CAUTIs
    Nursing evidence-based practice

    How One Institution Used Evidence-Based Practice to Reduce CAUTIs

    Catheter-associated urinary tract infections (CAUTIs) are associated with significant morbidity and mortality, with an estimated 93,300 urinary tract infections (UTIs) and 13,000 UTI-related deaths occurring each year in acute care hospitals. A preventable cause of UTIs is the use of long-term indwelling urinary catheters, an ideal focus of evidence-based practice initiatives.

    June 26, 2018
    Monitoring Document for Monoclonal Antibodies
    Oncology nurse influence

    Oncology Nurse Develops Monitoring Document for Monoclonal Antibodies

    It’s a rote but important phrase: Necessity is the mother of invention. When a need presents itself, developing novel, inventive solutions can lead to important change. But inventive change doesn’t have to come on a massive scale: small inventions can still have a big impact.

    June 22, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Bevacizumab in Combination With Chemotherapy for Ovarian Cancer

    June 14, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for Treatment of Relapsed or Refractory PMBCL

    June 14, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Mircera for Anemia Associated With Chronic Kidney Disease in Pediatric Patients on Dialysis

    On June 7, 2018, the U.S. Food and Drug Administration approved methoxy polyethylene glycol-epoetin beta (Mircera®, Vifor Pharma Inc.) for the treatment of pediatric patients aged 5–17 years on hemodialysis who are converting from another erythropoiesis-stimulating agent (ESA) after their hemoglobin level was stabilized with an ESA.

    June 12, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Venetoclax for CLL or SLL

    On June 8, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

    June 08, 2018
    Biosimilar to Pegfilgrastim
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Biosimilar to Pegfilgrastim to Decrease Cancer Treatment Infection Risk

    On June 4, 2018, the U.S. Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila) as a biosimilar to pegfilgrastim (Neulasta) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

    June 05, 2018
    The Intersection of Radiation and Medical Oncology Nursing
    Radiation therapy

    The Intersection of Radiation and Medical Oncology Nursing

    Misconceptions about radiation treatments, associated side effects, and impact on patient care still permeate medical oncology for patients and providers alike. As educators, patient advocates, and caregivers, radiation oncology nurses play a critical role in the successful treatment and support of patients with cancer.

    June 05, 2018
    Health Policy Advances Cancer Treatment Options in the Era of Biosimilars
    Health Policy

    Health Policy Advances Cancer Treatment Options in the Era of Biosimilars

    Options and cost are a double-edged sword as biomedical research marches forward and the list of approved drugs expands. More targeted drugs for specific diseases means that more patients have treatment plans that can directly fight their specific disease, possibly resulting in cures.

    June 04, 2018
    Which Breast Cancers Benefit from Treatment With Cyclin-Dependent Kinase 4/6 Inhibitor Treatment?
    Breast cancer

    Which Breast Cancers Benefit from Treatment With Cyclin-Dependent Kinase 4/6 Inhibitor Treatment?

    Which Breast Cancers Benefit from Treatment With Cyclin-Dependent Kinase 4/6 Inhibitor Treatment?

    A. Newly diagnosed DCIS  

    B. Metastatic, triple negative  

    C. Premenopausal, neoadjavant  

    D. ER+ metastatic

    May 31, 2018
    Overcome Barriers to Applying an Evidence-Based Process for Practice Change
    Putting evidence into practice (PEP)

    Overcome Barriers to Applying an Evidence-Based Process for Practice Change

    The evidence-based practice (EBP) process starts with a clinical question and then proceeds to searching and critically appraising the evidence. Once you have determined that a practice change is necessary, the next step is to integrate that evidence with clinical expertise and patient preferences and values. The last step in EBP is to evaluate the outcomes and disseminate the results. On paper, this flows in an orderly fashion. As clinicians, however, we know that it’s not often that easy or straightforward to change clinical practice. We often face barriers that can make it hard to change, but strategies exist to help facilitate practice change.

    May 30, 2018
    Here’s an Overview of the Types, Mechanisms, and Side Effects of Currently Approved Immunotherapies
    Immunotherapy

    Here’s an Overview of the Types, Mechanisms, and Side Effects of Currently Approved Immunotherapies

    Immunotherapy drugs fall into varying classes, each carrying its own mechanism of action and anticipated side effects. Although some side effects of immunotherapy may appear similar to those of chemotherapy (e.g., diarrhea, fatigue), they actually result from a totally different mechanism—meaning they require a different approach to management. Treating immunotherapy side effects as you would chemotherapy effects would likely result in patient harm.

    May 29, 2018
    What You Need to Know About Obtaining Informed Consent
    Oncology clinical trials

    What You Need to Know About Obtaining Informed Consent

    Informed consent is a comprehensive process as opposed to a check mark on a list of tasks to complete prior to starting cancer therapy. The American Society of Clinical Oncology/ONS Chemotherapy Administration Safety Standards explain that informed consent provides a patient with “sufficient information about the disease diagnosis and treatment options so that the individual can make a reasonable decision about treatment on the basis of an understanding of the potential risks and anticipated benefits of the treatment.”

    May 28, 2018
    Which Genetic Test Performed on Tumor Cells Has Prognostic and Predictive Uses?
    Genetics & genomics

    Which Genetic Test Performed on Tumor Cells Has Prognostic and Predictive Uses?

    Which Genetic Test Performed on Tumor Cells Has Prognostic and Predictive Uses? 

    A. BRCA1 test 

    B. CA 27.29 

    C. Circulating tumor cells

    D. Oncotype DX® 

    May 24, 2018
    • First page « First
    • Previous page
    • …
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Current page 7
    • Page 8
    • Page 9
    • Page 10
    • Page 11
    • …
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲